Abstract:Parkinson's disease (PD) is an age-associated neurodegenerative disorder characterized by the death of dopaminergic neurons in the substantia nigra pars compacta. Activation of 5-adenosine monophosphate-activated protein kinase (AMPK) has been suggested to be associated with PD pathogenesis. The aim of the present study was to investigate the effects of the aberrant expression of microRNA-185 (miR-185) in PD. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced in vitro model of PD was generated using the human SH-SY5Y dopaminergic neuroblastoma cell line, in order to examine the potential molecular mechanisms underlying the roles of miR-185 in PD. miR-185 expression was assessed in MPTP-treated SH-SY5Y cells using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, MPTP-treated SH-SY5Y cells were transfected with a miR-185 mimic or scramble miRNA, and flow cytometry was used to evaluate the level of cellular apoptosis. The expression of autophagy markers, including Beclin 1, microtubule-associated protein light chain 3 (LC3) I and LC3II, as well as key molecules involved in the AMPK/mechanistic target of rapamycin (mTOR) signaling pathway, such as phosphorylated (p)-AMPK and p-mTOR, was examined using RT-qPCR and western blot analyses. In addition, SH-SY5Y cells were treated with the AMPK inhibitor, Compound C, and its effects on cellular apoptosis were assessed. The results demonstrated that miR-185 was significantly downregulated in SH-SY5Y cells treated with MPTP at concentrations of >100 mu M when compared with untreated controls. Following transfection with a miR-185 mimic, miR-185 expression in SH-SY5Y cells was significantly increased when compared with blank control cells. Notably, miR-185 overexpression was revealed to significantly reduce the MPTP-induced increase in cellular apoptosis. In addition, the expression levels of Beclin 1, LC3I/II, p-AMPK and p-mTOR were significantly upregulated in MPTP-treated SH-SY5Y cells; whereas miR-185 overexpression significantly downregulated the expression of these factors. Furthermore, miR-185 overexpression significantly suppressed apoptosis of SH-SY5Y cells treated with MPTP plus Compound C when compared with the Compound C group. In conclusion, the results of the present study suggest that overexpression of miR-185 may inhibit autophagy and apoptosis of dopaminergic cells in PD potentially via regulation of the AMPK/mTOR signaling pathway. Therefore, AMPK/mTOR-mediated autophagy and apoptotic signaling pathways may be potential novel therapeutic targets for the development of alternative strategies for the treatment of patients with PD.

von Hippel-Lindau-targeting microRNA-143-3p attenuates mitochondrial abnormality via AMPK/PGC-1α axis in Parkinson's disease

Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3β/PP2A pathway in Parkinson's disease

Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism

Suppression Of Microrna-342-3p Increases Glutamate Transporters And Prevents Dopaminergic Neuron Loss Through Activating The Wnt Signaling Pathway Via P21-Activated Kinase 1 In Mice With Parkinson'S Disease

miR-103a-3p regulates mitophagy in Parkinson’s disease through Parkin/Ambra1 signaling

miR-214-3p promotes the pathogenesis of Parkinson's disease by inhibiting autophagy

Mir-141-3p Regulates Apoptosis and Mitochondrial Membrane Potential Via Targeting Sirtuin1 in a 1-Methyl-4-phenylpyridinium in Vitro Model of Parkinson's Disease.

Retracted: Suppression of Microrna‐342‐3p Increases Glutamate Transporters and Prevents Dopaminergic Neuron Loss Through Activating the Wnt Signaling Pathway Via P21‐activated Kinase 1 in Mice with Parkinson's Disease

Autophagy‐regulating miRNAs: Novel therapeutic targets for Parkinson's disease (Review)

Overexpression of Mir‑185 Inhibits Autophagy and Apoptosis of Dopaminergic Neurons by Regulating the AMPK/mTOR Signaling Pathway in Parkinson's Disease

Knockdown of JMJD1C, a Target Gene of Hsa-Mir-590-3p, Inhibits Mitochondrial Dysfunction and Oxidative Stress in MPP+-treated MES23.5 and SH-SY5Y Cells.

Knockdown of Long Non-Coding RNA AL049437 Mitigates MPP+ -Induced Neuronal Injury in SH-SY5Y Cells Via the Microrna-205-5p/mapk1 Axis.

Overexpression of PGC-1α Influences the Mitochondrial Unfolded Protein Response (mtupr) Induced by MPP+ in Human SH-SY5Y Neuroblastoma Cells

Resveratrol Inhibits VDAC1-Mediated Mitochondrial Dysfunction to Mitigate Pathological Progression in Parkinson's Disease Model

MiR-410 exerts neuroprotective effects in a cellular model of Parkinson's disease induced by 6-hydroxydopamine via inhibiting the PTEN/AKT/mTOR signaling pathway

Subcellular localization and function analysis of PINK1 mitron in PD progression: Mitron modulates mitochondrial morphology to regulate neuronal death

Targeting the RUNX3-miR-186-3p-DAT-IGF1R axis as a therapeutic strategy in a Parkinson's disease model

Mitochondrial Effects of PGC-1alpha Silencing in MPP+ Treated Human SH-SY5Y Neuroblastoma Cells

MicroRNA-409-3p Targeting at ATXN3 Reduces the Apoptosis of Dopamine Neurons Based on the Profile of Mirnas in the Cerebrospinal Fluid of Early Parkinson's Disease

Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson's disease

Regulatory mechanism of miR‐20a‐5p in neuronal damage and inflammation in lipopolysaccharide‐induced BV2 cells and MPTP‐HCl‐induced Parkinson's disease mice